Product Description
TRPA1 antagonist. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192962/)
Mechanisms of Action: TRPA1 Antagonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aalborg University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|